Exploring Novel Targeted Treatment Strategies for Optimal
Generalized Myasthenia Gravis Care
Podcast #2: Treatment Management With FcRn Antagonists
Pre-Test
Questions marked with a
*
are required
100%
Contact Information
First Name
Last Name
Email Address
Which of the following best describes the Myasthenia Gravis-Activities of Daily Living (MG-ADL) scale for
gMG?
Which of the following best describes the Myasthenia Gravis-Activities of Daily Living (MG-ADL) scale for gMG?
Clinician-rated assessment of the impact gMG on daily activities
Patient-reported assessment of the impact gMG on daily activities
Lower scores indicate greater impairment due to gMG
A and C
B and C
Which FcRn antagonist is most appropriate as an add-on therapy for a 46-year-old patient with anti-AChR-
positive gMG who travels out of state weekly for work?
Which FcRn antagonist is most appropriate as an add-on therapy for a 46-year-old patient with anti-AChR-positive gMG who travels out of state weekly for work?
Efgartigimod (intravenous infusion)
Efgartigimod (subcutaneous, self-administered)
Rozanolixizumab (subcutaneous infusion)
B and C
All of the above
Which FcRn antagonist is most appropriate as an add-on therapy for a 46-year-old patient with anti-MuSK-
positive gMG who travels out of state weekly for work?
Which FcRn antagonist is most appropriate as an add-on therapy for a 46-year-old patient with anti-MuSK-positive gMG who travels out of state weekly for work?
Efgartigimod (intravenous infusion)
Efgartigimod (subcutaneous, self-administered)
Rozanolixizumab (subcutaneous infusion)
B and C
All of the above
Done
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close
drag_indicator
Custom Title
highlight_off